|
Citius Pharmaceuticals Inc (NASDAQ: CTXR) |
|
Citius Pharmaceuticals Inc
CTXR's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Citius Pharmaceuticals Inc 's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 5.17 %
Citius Pharmaceuticals Inc net loss increased from $-8 millions, to $-11 millions in III. Quarter 2024,
• More on CTXR's Growth
|
|
Citius Pharmaceuticals Inc realized a net loss in trailing twelve months.
Citius Pharmaceuticals Inc realized cash reduction of $ -2.21 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
595.15 |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.88.
• More on CTXR's Valuation
|
|
|
|
|
Citius Pharmaceuticals Inc realized net loss in trailing twelve months.
Citius Pharmaceuticals Inc realized cash outflow of $ -2.21per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
595.15 |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.88.
Citius Pharmaceuticals Inc Price to Book Ratio is at 0.27 lower than Industry Avg. of 827.77. and higher than S&P 500 Avg. of 0.01
• More on CTXR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com